Breaking News
GSK
About GSK
A science-led global healthcare company with a special purpose: to help people do more, feel better, live longer. We have three global businesses that research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products. We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how and talented people.
GSK Receives US FDA File Acceptance for Jemperli (dostarlimab) plus Chemotherapy for the Treatment of dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer
June 6 2023
GSK has announced the US Food and Drug Administration (FDA) accepted the supplemental Biologics License […]
PathAI Announces Collaboration with GSK on NASH Phase 2b Clinical Trial
March 31 2023
PathAI, a leading provider of AI-powered pathology, today announced its partnership with GSK on HORIZON, […]
Phase III RUBY Clinical Trial Shows Jemperli Could Redefine Cancer Treatment
March 28 2023
GSK today announced interim results from Part 1 of the RUBY/ENGOT-EN-6-NSGO/GOG3031 phase III trial investigating […]
China National Medical Products Administration Accepts Regulatory Submission for Nucala (mepolizumab) in Severe Eosinophilic Asthma
March 14 2023
GSK today announced that the China National Medical Products Administration has accepted for review a […]
ViiV Healthcare announces positive data demonstrating long-acting injectable Cabenuva is as effective as daily oral Biktarvy for the treatment of HIV-1
February 23 2023
ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi […]
U.S. FDA Grants Regular Approval for Jemperli for the Treatment of Patients with Recurrent or Advanced Mismatch Repair-deficient Endometrial Cancer
February 10 2023
GSK reports that the US Food and Drug Administration (FDA) granted full approval for Jemperli (dostarlimab-gxly) […]
Jesduvroq Approved by US FDA for Anaemia of Chronic Kidney Disease in Adults on Dialysis
February 2 2023
GSK today announced that the US Food and Drug Administration (FDA) has approved Jesduvroq (daprodustat), […]
Iain Mackay, Chief Financial Officer, to Retire From GSK, Julie Brown Appointed as Successor
September 27 2022
GSK plc (LSE/NYSE: GSK) today announced that Iain Mackay, Chief Financial Officer (CFO), has decided […]
Zejula (Niraparib) Shows Durable and Sustained Long-term Progression-free Survival Benefit in the Prima Study of First-line Platinum-responsive Advanced Ovarian Cancer
September 12 2022
GSK plc (LSE/NYSE: GSK) today announced long-term data from the phase III PRIMA (ENGOT-OV26/GOG-3012) study […]
WHO Grants Prequalification to GSK’s Mosquirix – the First and Only Approved Malaria Vaccine
September 8 2022
GSK plc (LSE/NYSE: GSK) announced today that the World Health Organization (WHO) has awarded prequalification […]
Medable Selected by GSK to Power Decentralized and Hybrid Clinical Trials Across Global Product Portfolio
September 8 2022
Medable Inc., the leading software provider for patient-centered clinical trials, today announced that it has […]
GSK Completes Acquisition of Affinivax, Inc.
August 17 2022
GSK plc (LSE/NYSE: GSK) today announced it has completed the acquisition of Affinivax, Inc (Affinivax), a […]
Mersana Therapeutics Announces Substantial Co-Development and Commercialization Collaboration for an ImmunoADC Targeting HER2 Cancers with GSK
August 9 2022
Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a […]
GSK Signs Agreement to Support Pandemic Preparedness in Europe
July 29 2022
GSK plc (LSE/NYSE: GSK) today announced it had signed a framework contract with the European […]
GSK Announces £1 Billion R&D Investment Over Ten Years to Get Ahead of Infectious Diseases in Lower-income Countries
June 27 2022
GSK plc (LSE/NYSE: GSK) announced today an investment of £1bn over ten years to accelerate […]
GSK Presents Promising New Data for Bepirovirsen, an Investigational Treatment for Chronic Hepatitis B
June 27 2022
GSK plc today announced promising interim results from the B-Clear phase IIb trial showing that […]
Sanofi-GSK Next-generation COVID-19 Booster Delivers Strong Immune Response Against Variants of Concern, Including Omicron
June 14 2022
Sanofi today reports data from two trials, VAT02 Cohort 2 and COVIBOOST VAT013, conducted with […]
GSK to Acquire Clinical-stage Biopharmaceutical Company Affinivax, Inc.
June 1 2022
GSK plc (LSE/NYSE: GSK) today announced that it has entered into a definitive agreement to […]
GSK Announces Further Appointments to Designate Haleon Board
May 30 2022
GSK plc (LSE/NYSE: GSK) has today announced the appointments of Asmita Dubey, Marie-Anne Aymerich and […]
GSK Announces Dr Vishal Sikka to Join the Board as Non-executive Director
May 4 2022
GlaxoSmithKline plc (LSE/NYSE: GSK) has today announced that Dr Vishal Sikka, founder and CEO of […]
GSK Reaches Agreement to Acquire Late-stage Biopharmaceutical Company Sierra Oncology for $1.9bn
April 13 2022
GlaxoSmithKline plc (LSE/NYSE: GSK) and Sierra Oncology, Inc (Nasdaq: SRRA) today announced that the companies […]
Medicago and GSK Announce the Approval by Health Canada of COVIFENZ ®, an Adjuvanted Plant-based COVID-19 Vaccine
February 25 2022
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) today announced that Health […]
GSK Announces Positive Phase III Efficacy and Safety Data for Daprodustat in Patients with Anaemia Due to Chronic Kidney Disease
November 8 2021
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive results from the Phase III ASCEND (Anaemia Studies in […]
Viome Life Sciences Announces Expansion of Collaboration with GSK into New Therapeutic Interventions for Cancers and Autoimmune Diseases
October 20 2021
Viome Life Sciences, a mission-driven systems biology company aiming to help individuals improve their health, […]
Medicago and GSK Announce Positive Interim Phase 2 Results for Adjuvanted Covid-19 Vaccine Candidate
May 18 2021
Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) are pleased to report […]
Sanofi and GSK COVID-19 Vaccine Candidate Demonstrates Strong Immune Responses Across All Adult Age Groups in Phase 2 Trial
May 18 2021
The Sanofi and GSK adjuvanted recombinant COVID-19 vaccine candidate achieved strong rates of neutralizing antibody […]
GSK and VIR Biotechnology EMA Rolling Review of VIR-7831 (Sotrovimab)
May 7 2021
GlaxoSmithKline plc and Vir Biotechnology, Inc. today announced that the European Medicines Agency (EMA) has […]
EU Commission Approves Benlysta for Lupus Nephritis
May 5 2021
GlaxoSmithKline plc (GSK) today announced the European Commission has approved the expanded use of intravenous […]
ViiV Healthcare New Drug Application for Long-Acting Cabotegravir for Prevention of HIV
May 4 2021
ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (“GSK”), with Pfizer […]
FDA Grants Accelerated Approval for GSK’s JEMPERLI (dostarlimab-gxly) for Women with Recurrent or Advanced dMMR Endometrial Cancer
April 23 2021
GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has […]
Lilly, Vir, GSK Announce Positive Topline Data from Phase 2 BLAZE-4 Trial
March 30 2021
Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced […]
GSK to support manufacture of Novavax' COVID-19 vaccine
March 30 2021
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, GSK and the […]